Hippocampal serotonin depletion is related to the presence of generalized tonic-clonic seizures, but not to psychiatric disorders in patients with temporal lobe epilepsy

Imagem de Miniatura
Arquivos
art_FONSECA_Hippocampal_serotonin_depletion_is_related_to_the_presence_2015.PDF (954.18 KB)
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
Citação
EPILEPSY RESEARCH, v.111, p.18-25, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: Previous studies suggest that concentration of serotonin ([5-HT]) plays a pathogenic role in various types of epilepsy inhibiting seizures. However, most have not considered the clinical variables of epilepsy, and all of these studies included small and heterogeneous samples with refractory epilepsy, regardless of etiology. In this work, we measured [5-HT]s in hippocampal tissues from a large series of patients with refractory temporal lobe epilepsy caused by hippocampal sclerosis who underwent epilepsy surgery and evaluated the relationship between [5HT] and epilepsy-related clinical variables and psychiatric disorders. Methods: We included 44 patients with refractory unilateral TLE-HS who underwent surgical treatment for epilepsy. Hippocampal samples were collected, and serotonin concentrations were measured with high-pressure liquid chromatography (HPLC). Results: Lower [5-HT]s were correlated with a history of GTC seizures (Student's t-test: p0.041). There were no differences in [5-HT]s according to the other clinical variables and the presence of psychiatric disorders. Significance: Our findings demonstrated that serotonin depletion in the hippocampus play an important role in some aspects of the severity of epilepsy (i.e., the presence of GTC seizures) in a homogeneous sample of patients with refractory temporal lobe epilepsy determined by hippocampal sclerosis, but not with the presence of psychiatric disorders.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/9867
Referências
  1. Bagdy G, 2007, J NEUROCHEM, V100, P857, DOI 10.1111/j.1471-4159.2006.04277.x
  2. Beleza P, 2009, EUR NEUROL, V62, P65, DOI 10.1159/000222775
  3. Broderick PA, 2000, BRAIN RES, V878, P48, DOI 10.1016/S0006-8993(00)02678-0
  4. Browning RA, 1997, EUR J PHARMACOL, V336, P1, DOI 10.1016/S0014-2999(97)01215-6
  5. Cloix JF, 2010, EXP NEUROL, V225, P274, DOI 10.1016/j.expneurol.2010.05.023
  6. Clough RW, 1998, EPILEPSY RES, V29, P135, DOI 10.1016/S0920-1211(97)00076-4
  7. Coffey L.L., 1996, EPILEPSIA, V37, P189
  8. DAILEY JW, 1992, LIFE SCI, V50, P319, DOI 10.1016/0024-3205(92)90340-U
  9. DAILEY JW, 1989, EPILEPSY RES, V3, P3, DOI 10.1016/0920-1211(89)90063-6
  10. Drevets WC, 1999, BIOL PSYCHIAT, V46, P1375, DOI 10.1016/S0006-3223(99)00189-4
  11. Favale E, 2003, SEIZURE-EUR J EPILEP, V12, P316, DOI 10.1016/S1059-1311(02)00315-1
  12. FAVALE E, 1995, NEUROLOGY, V45, P1926
  13. Gattaz WF, 2011, J PSYCHIATR RES, V45, P1617, DOI 10.1016/j.jpsychires.2011.07.005
  14. Hasler G, 2007, BIOL PSYCHIAT, V62, P1258, DOI 10.1016/j.biopsych.2007.02.015
  15. Hung CF, 2011, NEUROSCI LETT, V504, P242, DOI 10.1016/j.neulet.2011.09.036
  16. Jobe PC, 2000, CNS DRUG REV, V6, P241
  17. JOBE PC, 1995, ITAL J NEUROL SCI, V16, P91, DOI 10.1007/BF02229080
  18. JOBE PC, 1986, LIFE SCI, V39, P775, DOI 10.1016/0024-3205(86)90455-8
  19. Kandratavicius L, 2013, J NEUROPATH EXP NEUR, V72, DOI 10.1097/NEN.0000000000000002
  20. Kandratavicius L, 2013, HIPPOCAMPUS, V23, P1212, DOI 10.1002/hipo.22160
  21. Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x
  22. Li BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093158
  23. LOUW D, 1989, CAN J NEUROL SCI, V16, P394
  24. Merrill MA, 2007, EPILEPSY RES, V76, P93, DOI 10.1016/j.eplepsyres.2007.07.002
  25. MORI A, 1987, RES COMMUN CHEM PATH, V56, P157
  26. NaffahMazzacoratti MG, 1996, EPILEPSY RES, V25, P133, DOI 10.1016/0920-1211(96)00030-7
  27. Pacia SV, 2001, BRAIN RES, V899, P106, DOI 10.1016/S0006-8993(01)02214-4
  28. Palomero-Gallagher N., 2012, EPILEPSIA, V3, P1987
  29. Picard M, 2011, NEUROSCI RES, V70, P313, DOI 10.1016/j.neures.2011.03.002
  30. PINTOR M, 1990, SYNAPSE, V5, P152, DOI 10.1002/syn.890050210
  31. Rocha L, 2012, NEUROBIOL DIS, V45, P499, DOI 10.1016/j.nbd.2011.09.006
  32. Ryu JR, 1999, EXP NEUROL, V156, P84, DOI 10.1006/exnr.1998.7003
  33. Sargent PA, 2000, ARCH GEN PSYCHIAT, V57, P174, DOI 10.1001/archpsyc.57.2.174
  34. Schenkel L.C., 2011, EPILEPSY RES, V12, P1
  35. Smolders I, 2008, NEUROPHARMACOLOGY, V54, P1017, DOI 10.1016/j.neuropharm.2008.02.006
  36. Specchio LM, 2004, CLIN NEUROPHARMACOL, V27, P133, DOI 10.1097/00002826-200405000-00009
  37. Trindade EM, 2008, EPILEPSY RES, V82, P194, DOI 10.1016/j.eplepsyres.2008.08.010
  38. Veriano Jr A., 2010, EPILEPSIA, V51, P921
  39. Vermoesen K, 2012, EPILEPSIA, V53, P870, DOI 10.1111/j.1528-1167.2012.03436.x
  40. YAN QS, 1994, EUR J PHARMACOL, V252, P105, DOI 10.1016/0014-2999(94)90581-9

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21
Artigos e Materiais de Revistas Científicas - LIM/27